Clinical-stage biotechnology company Ichnos Glenmark Innovation (IGI) on Monday presented promising full dose-escalation results from its Phase 1 TRIgnite-1 study of ISB 2001, an investigational first-in-class BCMA × CD38 × CD3-targeting trispecific antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).

These data, presented as a rapid oral presentation (Abstract #7514) at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, showed a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% across seven active dose levels (greater than 50 µg/kg) in a heavily pretreated patient population, with a favourable safety profile. The ORR was 74% in all treated patients, including two patients treated at lower dose levels.

ISB 2001 is designed to simultaneously target multiple myeloma by binding to the tumour-associated antigens BCMA and CD38, even when expressed at low levels, while engaging T cells to trigger an immune response.

ISB 2001 demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities reported.